U.S. FDA changes course and agrees to review Moderna's mRNA flu vaccine application
Moderna says the U.S. Food and Drug Administration (FDA) has agreed to review its influenza ‌vaccine, reversing an earlier decision to reject the application, following modifications from the company.
